SCHEMBL3761370

SCHEMBL3761370

Fc1ccccc1-n1nnc(-c2nc(-c3ccc(C(F)(F)F)nc3)no2)c1-c1ccncc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 6/20 0.46
CASP3 P42574 1/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
PKM P14618 1/20 0.41
KMT2A Q03164 1/20 0.41
TP53 P04637 4/20 0.40
LMNA P02545 1/20 0.40
S1PR3 Q99500 2/20 0.38
MAPT P10636 3/20 0.36
RXFP1 Q9HBX9 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10181634 0.93 S1PR1 (0.46) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL20405977 0.89 CASP3 (0.39) S1PR1CASP3NPC1RAB9ATP53
SCHEMBL3756298 0.88 NPC1 (0.47) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL10181614 0.87 S1PR1 (0.47) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL3750323 0.87 S1PR1 (0.45) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL3761084 0.86 NPC1 (0.54) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL3753060 0.85 S1PR1 (0.49) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL3760552 0.85 S1PR1 (0.45) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL3755430 0.85 NPC1 (0.50) S1PR1NPC1RAB9APKMKMT2A
SCHEMBL3760855 0.84 NPC1 (0.52) S1PR1NPC1RAB9APKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
WO-2009080663-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO S.A. (CH) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES OXA1L, RO60, PDCD11 S1PR1 517/4885CASP3 332/4885NPC1 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.